These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Probing intercellular interactions between vascular endothelial cadherin pairs at single-molecule resolution and in living cells. Panorchan P; George JP; Wirtz D J Mol Biol; 2006 May; 358(3):665-74. PubMed ID: 16540120 [TBL] [Abstract][Full Text] [Related]
28. The tumour necrosis factor-alpha induced vascular permeability is associated with a reduction of VE-cadherin expression. Hofmann S; Grasberger H; Jung P; Bidlingmaier M; Vlotides J; Janssen OE; Landgraf R Eur J Med Res; 2002 Apr; 7(4):171-6. PubMed ID: 12010652 [TBL] [Abstract][Full Text] [Related]
29. Dynamics of vascular endothelial-cadherin and beta-catenin localization by vascular endothelial growth factor-induced angiogenesis in human umbilical vein cells. Wright TJ; Leach L; Shaw PE; Jones P Exp Cell Res; 2002 Nov; 280(2):159-68. PubMed ID: 12413882 [TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin-dependent mechanism. Hrgovic I; Doll M; Pinter A; Kaufmann R; Kippenberger S; Meissner M Exp Dermatol; 2017 Feb; 26(2):194-201. PubMed ID: 27487811 [TBL] [Abstract][Full Text] [Related]
36. Modulation of VE-cadherin and PECAM-1 mediated cell-cell adhesions by mitogen-activated protein kinases. Wu J; Sheibani N J Cell Biochem; 2003 Sep; 90(1):121-37. PubMed ID: 12938162 [TBL] [Abstract][Full Text] [Related]
37. Cardiac ischemia activates vascular endothelial cadherin promoter in both preexisting vascular cells and bone marrow cells involved in neovascularization. Kogata N; Arai Y; Pearson JT; Hashimoto K; Hidaka K; Koyama T; Somekawa S; Nakaoka Y; Ogawa M; Adams RH; Okada M; Mochizuki N Circ Res; 2006 Apr; 98(7):897-904. PubMed ID: 16543497 [TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Kawamura H; Li X; Harper SJ; Bates DO; Claesson-Welsh L Cancer Res; 2008 Jun; 68(12):4683-92. PubMed ID: 18559514 [TBL] [Abstract][Full Text] [Related]
39. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development. Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749 [TBL] [Abstract][Full Text] [Related]
40. Biosynthesis and expression of VE-cadherin is regulated by the PI3K/mTOR signaling pathway. Bieri M; Oroszlan M; Zuppinger C; Mohacsi PJ Mol Immunol; 2009 Feb; 46(5):866-72. PubMed ID: 18990449 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]